Bolek EC - Search Results

1

COVID-19 Among Patients With Inflammatory Rheumatic Diseases.

Esatoglu SN, Tascilar K, Babaoğlu H, Bes C, Yurttas B, Akar S, Pehlivan O, Akleylek C, Tecer D, Seyahi E, Yuce-Inel T, Alpay-Kanitez N, Bodakci E, Tekgoz E, Colak S, Bolek EC, Koca SS, Kalyoncu U, Icacan OC, Ugurlu S, Oz HE, Hamuryudan V, Hatemi G; Turkish Society for Rheumatology COVID-19 Registry Investigators. Esatoglu SN, et al. Among authors: bolek ec. Front Immunol. 2021 Apr 16;12:651715. doi: 10.3389/fimmu.2021.651715. eCollection 2021. Front Immunol. 2021. PMID: 33936073 Free PMC article.

2

Rare occupational cause of nasal septum perforation: Nickel exposure.

Bolek EC, Erden A, Kulekci C, Kalyoncu U, Karadag O. Bolek EC, et al. Int J Occup Med Environ Health. 2017 Oct 6;30(6):963-967. doi: 10.13075/ijomeh.1896.01019. Epub 2017 Aug 23. Int J Occup Med Environ Health. 2017. PMID: 28839290 Free article.

3

The clinical features and outcomes of Turkish patients with IgG4-related disease:a single-center experience.

Karadağ Ö, Erden A, Ayhan EA, Bölek EÇ, Kalyoncu U, Armağan B, Sarı A, Kılıç L, Akdoğan A, Hazırolan T, Akdoğan B, Apraş Bilgen ŞŞ, Baydar D, Kiraz S, Ertenli Aİ. Karadağ Ö, et al. Among authors: bolek ec. Turk J Med Sci. 2017 Nov 13;47(5):1307-1314. doi: 10.3906/sag-1704-150. Turk J Med Sci. 2017. PMID: 29151297 Free article.

4

Successful Treatment of Amyloid A-Type Amyloidosis Due to Behçet Disease With Tocilizumab.

Ilbay A, Erden A, Sari A, Armagan B, Aktas BY, Bolek EC, Kalyoncu U, Karadag O. Ilbay A, et al. Among authors: bolek ec. J Clin Rheumatol. 2019 Jun;25(4):43-45. doi: 10.1097/RHU.0000000000000724. J Clin Rheumatol. 2019. PMID: 29470263 No abstract available.

5

Some concerns from Turkey.

Bilgin E, Ozarli İ, Kılıç L, Bölek EÇ, Yardımcı GK, Karadağ Ö. Bilgin E, et al. Among authors: bolek ec. Ann Rheum Dis. 2020 Feb;79(2):e15. doi: 10.1136/annrheumdis-2018-214739. Epub 2018 Nov 24. Ann Rheum Dis. 2020. PMID: 30472654 No abstract available.

6

Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.

Oral F, Bilgin E, Bölek EÇ, Yardımcı GK, Kılıç L. Oral F, et al. Among authors: bolek ec. Rheumatology (Oxford). 2019 May 1;58(5):925. doi: 10.1093/rheumatology/kez033. Rheumatology (Oxford). 2019. PMID: 30809674 No abstract available.

7

Interferon alpha might be an alternative therapeutic choice for refractory Neuro-Behçet's disease.

Bolek EC, Sari A, Kilic L, Karadag O. Bolek EC, et al. Mult Scler Relat Disord. 2019 Apr;29:153. doi: 10.1016/j.msard.2019.01.015. Epub 2019 Jan 6. Mult Scler Relat Disord. 2019. PMID: 30885370 No abstract available.

8

Do ANCA-associated vasculitides and IgG4-related disease really overlap or not?

Erden A, Bolek EC, Yardimci KG, Kilic L, Bilgen SA, Karadag O. Erden A, et al. Among authors: bolek ec. Int J Rheum Dis. 2019 Oct;22(10):1926-1932. doi: 10.1111/1756-185X.13693. Epub 2019 Sep 30. Int J Rheum Dis. 2019. PMID: 31571413

9

Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience.

Bolek EC, Sari A, Kilic L, Kalyoncu U, Kurne A, Oguz KK, Topcuoglu MA, Ertenli I, Karadag O. Bolek EC, et al. Mult Scler Relat Disord. 2020 Feb;38:101512. doi: 10.1016/j.msard.2019.101512. Epub 2019 Nov 9. Mult Scler Relat Disord. 2020. PMID: 31733425

10

Management of Behcet's syndrome.

Karadag O, Bolek EC. Karadag O, et al. Among authors: bolek ec. Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii108-iii117. doi: 10.1093/rheumatology/keaa086. Rheumatology (Oxford). 2020. PMID: 32348509 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page